Shares of GoodRx Holdings (NASDAQ:GDRX) closed trading on Thursday with a significant loss of over 18%, following the company’s announcement of its third-quarter results.
The company reported quarterly revenue of $180 million, which marks a 4% decrease compared to the same period last year. This figure fell short of the Street estimate of $188.52 million. The earnings per share (EPS) for the third quarter stood at $0.06, aligning with the estimates anticipated by Wall Street.
Looking ahead to the fourth quarter of 2023, GoodRx anticipates its revenue to be in the range of $188 million to $194 million. This forecast is slightly below the Street estimate of $192.7 million.
For the entire year, the company projects its revenue to be between $742 million and $748 million. This projection is lower than the Street estimate of $754.9 million.